Cooper Companies stock
COONASDAQThe Cooper Companies, Inc., HealthcareISIN US2166485019
61Score 61 out of 100, Neutral
Price and trend
61 / 100
Price history
−12% in one yearThe chart shows daily closes over 20 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.
Below the 200-day line: the price is 7.7% below it.
Since April 2026 the 50-day line has been below the 200-day line; the trend has turned down.
Normal: the price is neither overheated nor sold off (RSI 54).
The price is 25% below its 52-week high. Largest decline in 20 years: 80% (May 2007 to November 2008).
Chart figures for advanced users
- SMA 50$58.80
- Average price of the last 50 trading days, shows the short-term trend.
- SMA 200$68.14
- Average price of the last 200 trading days, shows the long-term trend.
- RSI (14)54
- Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
- MACDabove the signal line
- Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
- Support$53.27
- The lowest closing price of the last twelve months.
- Resistance$84.32
- The highest closing price of the last twelve months.
Snapshot
Computed from the data by fixed rules, no AI
- The Cooper Companies, Inc. belongs to the Medical (Instruments & Supplies) industry (United States) and, with a market value of $11.97B, is number 14 of 44 companies in its industry on MEQIRI.
- In fiscal 2025 it reported revenue of $4.09B (up 5.1% year on year) and earnings of $374.9M (down 4.4%).
- For fiscal 2026, analysts expect on average revenue of $4.24B (up 3.6%) and adjusted earnings per share of $4.53 (up 9.7%).
Show more
- MEQIRI Score 61 out of 100 (Neutral): rank 261 of 714 in Healthcare, median 53.
- The P/E is 21.3 (Medical (Instruments & Supplies) median 34.8, own median of recent years 19.5).
- Our model puts fair value at $78.05, with the price 19% below it.
In plain words
The numbers on this page in plain words, written by an AI
Strengths
- Consistently profitableProfit in all 10 fiscal years from 2016 to 2025.Fundamentals 82
- Earnings turn into cashFree cash flow 119% of earnings over the last 12 months.Fundamentals 82
Weaknesses
- Earnings per share fallingDown 17.3% a year since 2020.Growth 55
Its standout strength is fundamentals, while capital allocation holds the score back.
Daily figure as of 12 Nov 2026
How the score is calculatedScore overview
Fundamentals are strong, with stable profits and strong cash generation.
Score history
The full history of up to 20 years comes with MEQIRI Pro.
See plansCrash risk medium
How well MEQIRI warnsIn the middle among smaller stocks.
From 2016 to 2025, 20 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.
What lowers it
- solid fundamentals
Valuation
Valuation signal
Modestly undervaluedIn our model the price counts as cheap below $60.04 and expensive above $111.50 (uncertainty medium, based on the price swings of the past year).
The two parts of the fair value come to $53.57 (cash-flow model) and $102.53 (industry comparison), and the gap between them shows how uncertain the estimate is.
Calculated with a cost of equity of 8.8%. At 9.8% the fair value would be $73.48, at 7.8% it would be $84.91.
Valuation metrics
Half from the cash-flow model, half from earnings times the industry P/E (34.8).
Calculate with your own assumptionsCompany performance
This shows several years of history with an automatic assessment.
Revenue
In the twelve months to 31 Jul 2026, revenue rose 4.7% on the twelve months before. Revenue has grown solidly since 2006, at about 9% per year.
Margins
- Gross margin
- Operating margin
- Net margin
In fiscal 2025: gross 61%, operating 17%, net 9%.
Debt & balance sheet
latest quarterModerate debt, and interest is adequately covered.
Earnings
- Next earnings
- 3 Dec 2026in 21 days
- Last reported
- 9 Sep 2026EPS reported $1.15 (expected $1.12)above expectations
Analyst estimates
Earnings estimates have barely changed since 15 Oct 2026.
- Earnings per share
- $4.68−0.5%
- Revenue
- $4.41B0.0%
- Earnings per share
- $5.08−0.5%
- Revenue
- $4.62B−0.1%
MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.
Company outlook lowered
Share price after the results: −20.0%CooperVision revenue guidance was reduced because of channel inventory, and Q4 margins are expected to be pressured by higher investments and FX headwinds.
“In summary, we expect Q4 to be broadly similar to Q3, with the primary differences being greater commercial investments in CooperVision, additional FX headwinds and lower tariff refunds, which will pressure gross and operating margins.”The outlook is not part of the score and not a recommendation to buy or sell.
From the earnings call on 9 Sep 2026 (fiscal Q3 2026), read by AI.
Insiders
Open-market purchases and sales by executives, board members and major holders
3 insiders bought on the open market between 11 Sept 2026 and 16 Sept 2026, $1.88M in total.
Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.
What happened at Cooper Companies
The key events of the last six months from our own data. A click takes you to the matching card.
Sector comparison
714 rated companies in Healthcare
- This company
- 61
- Sector median
- 53
Categories against the sector median
The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.
Competitors in Medical (Instruments & Supplies)
The next larger and next smaller companies by market value
- SartoriusSRT.DE $17.6B59
- ColoplastCOLO-B.CO $16.54B69
- SolventumSOLV $15.06B61
- Baxter InternationalBAX $13.63B47
- RepligenRGEN $11.03B51
- AvantorAVTR $10.66B53
- AptarGroupATR $9.07B65
- Bausch + LombBLCO $7.62B50
ETFs that hold Cooper Companies
Held by 89 ETFs on Xetra. Shown per index: the ETF with the largest weight.
| ETF | Weight | Cost | Fund size |
|---|---|---|---|
| Invesco NASDAQ Next Generation 100 UCITS ETF AccEQQJ | 0.63% | 0.25% | €44.3M |
| iShares Ageing Population UCITS ETF2B77 | 0.45% | 0.40% | €807M |
| iShares MSCI USA Mid-Cap Equal Weight UCITS ETFQDVC | 0.33% | 0.20% | €268.74M |
Show 5 more
| Xtrackers S&P 500 Equal Weight UCITS ETF 1CXDEW | 0.20% | 0.15% | €14.88B |
| State Street SPDR S&P U.S. Health Care Select Sector UCITS ETF (Acc)ZPDH | 0.18% | 0.15% | €592.11M |
| iShares S&P 500 Health Care Sector UCITS ETFQDVG | 0.18% | 0.15% | €3.27B |
| Xtrackers MSCI USA Health Care UCITS ETF 1DXUHC | 0.18% | 0.12% | €1.34B |
| iShares MSCI World Value Factor Advanced UCITS ETFCBUI | 0.14% | 0.25% | €1.53B |
Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).
Data status and sources
- Score
- Daily value of 12 Nov 2026, recalculated nightly
- Price
- Closing price of 11 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Oct 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral, published since 7 Nov 2026 (in the score history since 4 Sep 2026)
- Valuation signal Fairly valued since 7 Nov 2026
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.